The large scale production of all cannabinoids could soon be possible thanks to a biotech company based in Hungary.
Sundial Growers and the University of Saskatchewan have just agreed to investigate the use of cannabis to treat dementia as part of 3 year agreement.
The overarching goals of this study are to oinvestigate the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences.
"As puberty is a critical window of physical growth and development, it is critical to fully understand what impact cannabis consumption can have." Constantine Samaan, associate professor of the Department of Pediatrics, McMaster University.
The lead author of the related paper commented: “Based on one of the largest brain imaging studies ever done, we can now track common disorders and behaviors that prematurely age the brain."
The concurrent and lasting effects of adolescent cannabis on important cognitive functions have now been observed and appear to be more pronounced than those observed for alcohol.
The company says they have developed an innovative approach, leveraging microarray technology to determine the quantity of microbial content in a sample relative to a specific testing standard.
Cannabinoid drugs do not appear to reduce the intensity of experimental pain, but, instead, may make pain feel less unpleasant and more tolerable.
The lab will move to a centrally located 5,000 square foot facility that to serve marijuana establishments statewide.
Phase I/II clinical trial will be first of its kind to explore cannabis as a potential treatment option for essential tremor.